02.11.10
Daiichi Sankyo, Inc. received approval from the FDA for its hypertension treatment Benicar (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age.
“As hypertension is on the rise also in a younger population, Daiichi Sankyo believes it is important to help doctors meet the challenge of treating these pediatric patients by providing a treatment option to help people effectively manage their hypertension,” said Reinilde Heyrman, M.D., vice president clinical development, operations, Daiichi Sankyo Pharma Development.
The approval was based on a Phase III study examining the antihypertensive effects of Benicar in pediatric patients. The study found the drug to be safe and effective in children ages 6-16 with hypertension, resulting in statistically significant blood pressure reductions compared to placebo. Benicar was originally approved for the treatment of hypertension in adults in 2002.
“As hypertension is on the rise also in a younger population, Daiichi Sankyo believes it is important to help doctors meet the challenge of treating these pediatric patients by providing a treatment option to help people effectively manage their hypertension,” said Reinilde Heyrman, M.D., vice president clinical development, operations, Daiichi Sankyo Pharma Development.
The approval was based on a Phase III study examining the antihypertensive effects of Benicar in pediatric patients. The study found the drug to be safe and effective in children ages 6-16 with hypertension, resulting in statistically significant blood pressure reductions compared to placebo. Benicar was originally approved for the treatment of hypertension in adults in 2002.